Overview

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Status:
Not yet recruiting

Trial end date:
2024-09-05

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Dulaglutide
Tirzepatide